Management of Atrial Fibrillation and Congestive Heart Failure

Anticoagulation Management

The European Society of Cardiology recommends direct oral anticoagulants (DOACs) in preference to vitamin K antagonists in eligible patients with atrial fibrillation (AFib) for stroke prevention 1, 2
Patients with a CHA₂DS₂-VA score of at least 4, indicating a high risk of stroke, should receive continued anticoagulation 2
Therapeutic anticoagulation should be maintained indefinitely in patients with multiple risk factors for thromboembolism, such as congestive heart failure (CHF) and AFib 1, 3
The American College of Cardiology recommends evaluating for modifiable bleeding risk factors while maintaining anticoagulation, as discontinuation would significantly increase stroke risk 1, 2

For patients with AFib and reduced left ventricular ejection fraction (LVEF ≤40%), the American College of Cardiology recommends beta-blockers and/or digoxin as first-line therapy for heart rate control 1, 4
If the patient has preserved LVEF (>40%), beta-blockers, diltiazem, verapamil, or digoxin can be used as first-line agents, according to the European Society of Cardiology 1
The American College of Cardiology advises avoiding non-dihydropyridine calcium channel antagonists (diltiazem, verapamil) in patients with decompensated heart failure, as these may worsen hemodynamic compromise 6
Target heart rate should be controlled to improve symptoms, with a lenient control target (heart rate <110 bpm) being as effective as strict rate control (heart rate <80 bpm at rest) in stable patients, as recommended by the American College of Cardiology 6

The American College of Cardiology recommends initiating statin therapy for cardiovascular risk reduction in patients with elevated LDL cholesterol, such as those with CHF and AFib 4, 7
Statin therapy is indicated for patients with elevated LDL and multiple cardiovascular risk factors, despite not being beneficial when prescribed solely for heart failure, according to the American Heart Association 8
Moderate to high-intensity statin therapy is appropriate for patients with high cardiovascular risk profiles, such as those with CHF and AFib, as recommended by the American College of Cardiology 4

The American College of Cardiology recommends optimizing guideline-directed medical therapy (GDMT) for heart failure, including ACE inhibitors/ARBs/ARNI for patients with HFrEF, beta-blockers, aldosterone antagonists, and diuretics as needed 4, 8
Regular monitoring should include assessment of heart failure symptoms, volume status, heart rate control in AFib, renal function, and lipid levels to assess response to statin therapy, as recommended by the American College of Cardiology 1, 4, 7, 8